Quantbot Technologies LP Purchases 59,445 Shares of Simulations Plus, Inc. $SLP

Quantbot Technologies LP lifted its position in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 5,944,500.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,446 shares of the technology company’s stock after buying an additional 59,445 shares during the period. Quantbot Technologies LP owned about 0.30% of Simulations Plus worth $896,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Simulations Plus by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock valued at $233,000 after acquiring an additional 390 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Simulations Plus by 5.7% during the 2nd quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company’s stock worth $300,000 after acquiring an additional 930 shares in the last quarter. Invesco Ltd. grew its stake in shares of Simulations Plus by 3.8% during the 2nd quarter. Invesco Ltd. now owns 36,452 shares of the technology company’s stock worth $636,000 after acquiring an additional 1,323 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Simulations Plus in the second quarter valued at approximately $25,000. Finally, US Bancorp DE raised its holdings in shares of Simulations Plus by 32.5% in the third quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock valued at $93,000 after purchasing an additional 1,513 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Price Performance

Shares of SLP opened at $12.22 on Friday. The company’s 50-day moving average is $16.05 and its 200-day moving average is $16.38. The firm has a market capitalization of $246.23 million, a PE ratio of -3.82 and a beta of 1.17. Simulations Plus, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $36.45.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). The company had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same quarter last year, the company posted $0.17 EPS. Analysts predict that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SLP shares. TD Cowen restated a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research note on Thursday, December 18th. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Finally, Zacks Research downgraded shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $25.00.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.